证券代码：300856 证券简称：科思股份 公告编号：2023-060 债券代码：123192 债券简称：科思转债 南京科思化学股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 （一）首次公开发行股票募集资金 1、实际募集资金金额及到位情况 根据中国证券监督管理委员会证监许可【2020】803 号《关于核 准南京科思化学股份有限公司首次公开发行股票的批复》文件核准， 南京科思化学股份有限公司（以下简称"公司""本公司"）由主承销 商民生证券股份有限公司（以下简称"民生证券"）向社会公众公开 发行人民币普通股（A 股）2,822 万股，每股面值 1.00 元，发行价为 每股 30.56 元，共募集资金 86,240.32 万元，扣除发行费用 7,727.21 万元后，实际募集资金净额为 78,513.11 万元。上述募集资金到位情 况已经天衡会计师事务所（特殊普通合伙）出具的天衡验字（2020） 00071 号《验资报告》验证。 2、以前年度募集资金使用及结余情况 截至 202 ...

独立董事对第三届董事会第十三次会议 二、关于公司控股股东及其他关联方占用公司资金和公司对外担保情况 经核查，报告期内，公司严格执行相关法律、法规、规范性文件和《公司章 程》的规定，不存在控股股东及其他关联方非经营性占用公司资金的情况和公司 违规对外担保情况，也不存在以前年度发生并延续至报告期的前述情况。 独立董事：宋兵、崔荣军、郭燏 2023 年 8 月 17 日 南京科思化学股份有限公司 相关事项的独立意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）、中国证券监督管 理委员会《上市公司独立董事规则》《南京科思化学股份有限公司章程》（以下简 称"《公司章程》"）等有关法律、行政法规和规范性文件，我们作为南京科思化 学股份有限公司（以下简称"公司"）的独立董事，对提交公司第三届董事会第 十三次会议审议的相关议案以及关于公司控股股东及其他关联方占用公司资金 和公司对外担保情况进行了审阅。经认真审查相关文件，发表独立意见如下： 一、关于公司《2023 年半年度募集资金存放与使用情况的专项报告》的议 案 经认真审议，我们认为公司编制的《2023 年半年度募集资金存放与使用情 况的专项报告》如实反映了公司 ...

证券代码：300856 证券简称：科思股份 公告编号：2023-057 债券代码：123192 债券简称：科思转债 南京科思化学股份有限公司 第三届监事会第十二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 南京科思化学股份有限公司（以下简称"公司"）第三届监事会 第十二次会议于 2023 年 8 月 17 日以现场结合通讯方式召开，会议通 知已于 2023 年 8 月 7 日以通讯方式通知了全体监事。会议应出席监 事 3 名，实际出席监事 3 名（其中 1 名监事以通讯方式出席）。会议 由监事会主席刘建生先生主持，公司董事会秘书列席了本次会议。 本次监事会会议的召集、召开和表决程序符合有关法律、行政法 规、部门规章、规范性文件和《公司章程》的规定。 二、监事会会议审议情况 经与会监事认真审议，形成决议如下： （一）审议通过《关于公司<2023 年半年度报告>及其摘要的议 案》 根据 2023 年半年度经营情况，公司按照相关规定编制了《2023 年半年度报告》及《2023 年半年度报告摘要》。 本 议 案 具 体 内 容 ...

南京科思化学股份有限公司 单位：人民币万元 非经营性资金占用 资金占用方名 称 占用方与上 市公司的关 联关系 上市公司 核算的会 计科目 2 023 年期 初占用资 金余额 2 023 年上半年占 用累计发生金额 （不含利息） 2023 年上半年 占用资金的利息 （如有） 2023 年上半年 偿还累计发生 金额 2023 年上半年 期末占用资金 余额 占用形成 原因 占用性质 控股股东、实际控制人及其附属企业 不适用 不适用 不适用 不适用 不适用 小计 - - - - - 前控股股东、实际控制人及其附属企业 不适用 不适用 不适用 不适用 不适用 小计 - - - - - 其他关联方及附属企业 不适用 不适用 不适用 不适用 不适用 小计 - - - - - 总计 - - - - - 其它关联资金往来 资金往来方名 称 往来方与上 市公司的关 联关系 上市公司 核算的会 计科目 2023 年期 初往来资 金余额 2023 年上半年往 来累计发生金额 （不含利息） 2023 年上半年 往来资金的利息 （如有） 2023 年上半年 偿还累计发生 金额 2023 年上半年 期末往来资金 余额 往来形成 原因 往 ...

中信证券股份有限公司 关于南京科思化学股份有限公司 2023 年半年度跟踪报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称：科思股份 | | --- | --- | | 保荐代表人姓名：王风雷 | 联系电话：021-20262057 | | 保荐代表人姓名：艾华 | 联系电话：021-20262205 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次 | 0 次 | | 数 | | | 2．督导公司建立健全并有效执行规章制 | | | 度的情况 | | | （1）是否督导公司建立健全规章制度（包 括但不限于防止关联方占用公司资源的 | 是 | | 制度、募集资金管理制度、内控制度、内 | | | 部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 共查询 6 次（每月 1 次） | | （2）公司募集资金项目进展是否与信息 | 是 ...

Business Strategy and Future Plans - The company's future strategy focuses on strengthening and expanding its core businesses of synthetic fragrances and cosmetic active ingredients, aiming to enhance its competitive advantages and international brand influence [3] - Sunscreen products will remain the mainstay of the business, with continued expansion in fragrance, personal care, and other functional personal care product ingredients [3] - The company plans to become a comprehensive supplier of daily chemical raw materials, leveraging its efficient R&D and industrialization capabilities [3] - In the short to medium term, the company will not engage in terminal cosmetics business but will continue to focus on personal care product ingredients [3] - The company is optimistic about the domestic market and has established partnerships with leading domestic brands, planning to continue advancing related businesses [4] Product Development and Market Performance - The company's PA product, which started production in the first half of last year, is expected to see a significant increase in sales this year [4] - Titanium dioxide product, which began trial production at the end of last year, is expected to gradually increase in volume in the second half of this year [4] - Amino acid surfactants, PO, and new P-S production lines are under construction, with a focus on market promotion and customer certification this year [4] - The company's sunscreen products have high gross and net profit margins, with significant barriers to entry for potential competitors [2] - The company has a competitive advantage in product structure, innovation, R&D capabilities, production and quality management systems, and global responsiveness [2] Cost and Pricing - The company's main raw materials include bulk and fine chemicals, with prices influenced by upstream crude oil and other bulk commodity price fluctuations [3] - In cases of significant raw material price increases, the company actively negotiates price adjustments with downstream customers, though there may be delays due to pricing cycles and market competition [3] - Raw material costs have slightly decreased compared to the third quarter of last year, but product prices are not fully synchronized with crude oil prices [5] - The company expects overall price trends to remain stable this year, given strong market demand and customer feedback [5] Sales and Distribution - For large and medium-sized terminal customers, the company primarily uses its own sales system for direct sales [5] - For geographically concentrated but smaller customers, the company relies on distributors to improve efficiency and reduce costs [5] - The two sales models complement each other and do not conflict [5] Human Resources and Organizational Development - The company places a high priority on human resources, continuously improving its talent pool and conducting multi-level talent reserves aligned with its business direction and future development strategy [4] - The company has implemented its first post-listing equity incentive plan and plans to conduct equity incentives every 2-3 years to motivate employees and focus on long-term development [4] - The company's core values emphasize innovation and continuous improvement, aiming to integrate macro concepts into daily work details [4] Industry Barriers and Competitive Landscape - The cosmetic active ingredient market is highly concentrated, with a stable supplier system and high standards for supplier certification, making it difficult for new entrants to gain significant customer resources in the short term [2] - The company has established a strong position in the international cosmetics supply chain through technological innovation and stable quality, continuously increasing its market share [3]

证券代码：300856 证券简称：科思股份 编号：2023-002 南京科思化学股份有限公司 投资者关系活动记录表 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称及 人员姓名 南京科思化学股份有限公司 2022 年度业绩说明会采用网络远程 方式进行，面向全体投资者 时间 2023 年 5 月 25 日 15:00-17:00 地点 全景网"投资者关系互动平台"（http://ir.p5w.net） 上市公司接待人 员姓名 董事、总裁 杨军先生 董事、副总裁兼董事会秘书 曹晓如先生 独立董事 郭燏先生 财务总监 孟海斌先生 保荐代表人 王风雷先生 投资者关系活动 主要内容介绍 1、公司一季度业绩大增的因素构成，二季度能否维持高增 速？ 2023 年一季度营业收入同比增长主要系本期化妆品活性成 分产品销售量同比增长较大，净利润同比增长主要系公司 2021 年四季度以来基于原材料和海运费价格大幅上涨采取的产品价 格调整措施逐步落地，以及公司整体产能利用率的提升和新产品 产能的逐步释放等因素影响。 目前，公司生产销售正常，总体市场 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 南京科思化学股份有限公司（以下简称"公司"）《2022 年年度报 告 》 及 其 摘 要 已 于 2023 年 4 月 20 日在巨潮资讯网 （www.cninfo.com.cn）上披露。为使广大投资者更全面深入地了解 公司 2022 年度的经营情况，公司将于 2023 年 5 月 25 日（星期四） 15:00-17:00 举办 2022 年度业绩说明会。本次说明会将采用网络远 程的方式举行，投资者可登陆全景网"投资者关系互动平台" （http://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事兼总裁杨军先生、独立董事 郭燏先生、财务总监孟海斌先生和董事、副总裁兼董事会秘书曹晓如 先生以及保荐代表人王风雷先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业 绩说明会提前向投资者公开征集相关问题。投资者可于 2023 年 5 月 23 日（星期二）15：00 前访问 http://ir.p5w.net/zj/，或扫描下方 二维码，进入问题征集专题页面。公司将在 ...

南京科思化学股份有限公司 投资者关系活动资料 证券代码：300856 证券简称：科思股份 编号：2023-001 南京科思化学股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|---------------------------|-----------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 | | | | | □新闻发布会 □路演活动 | | | 类别 | | | | | □现场参观 | | | | 其他 线上会议 | | | | | 中金公司、中信证券、东吴证券、华泰证券、富国基金、嘉实基 | | 参与单位名称及 | | | | | | 金、鹏华基金、汇添富基金、中欧基金、中信建投资管等 280 个 | | 人员姓名 | | | | | 机构及个人参会 | | | 时间 | 2023 年 4 月 26 日 | | 地点 电话会议 上市公司接待人 员姓名 董事、董事会秘书 曹晓如 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥587,793,946.66, representing a 42.33% increase compared to ¥412,987,742.55 in the same period last year[4] - The net profit attributable to shareholders for Q1 2023 was ¥160,229,516.90, a significant increase of 176.13% from ¥58,026,624.51 in the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥157,144,785.08, reflecting a 198.10% increase from ¥52,715,485.14 year-on-year[4] - Net profit attributable to shareholders grew by 176.13%, while net profit excluding non-recurring items increased by 198.10%[38] - The total comprehensive income for Q1 2023 was ¥159,302,758.76, up from ¥57,960,323.46, which is an increase of about 174.5% year-over-year[65] - The basic and diluted earnings per share for Q1 2023 were both ¥0.9463, compared to ¥0.3427 in the same quarter last year, marking an increase of approximately 176.5%[65] Operating Costs and Expenses - The total operating costs for Q1 2023 were ¥396,559,739.94, up from ¥351,684,030.22 in the same period last year[15] - Research and development expenses for Q1 2023 amounted to ¥31,263,696.98, compared to ¥14,921,949.46 in the previous year, indicating a significant increase in investment in innovation[15] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of ¥171,958,040.51, a turnaround from a negative cash flow of -¥13,952,287.97 in the same period last year[17] - The net cash flow from operating activities reached ¥171,958,040.51, a year-on-year increase of 1,332.47%[41] - The cash received from sales of goods and services was ¥541,873,945.65, compared to ¥356,970,397.61 in the previous period, indicating an increase of approximately 51.6%[51] - The cash and cash equivalents at the end of the reporting period were ¥329,229,925.89, down from ¥544,168,486.03 at the beginning of the year[12] - The cash and cash equivalents at the end of the period were ¥329,229,925.89, down from ¥544,118,274.13 at the beginning of the period[28] - The company reported a decrease in other comprehensive income, with a net amount of -¥926,758.14 for Q1 2023 compared to -¥66,301.05 in the previous year[65] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥2,477,888,881.18, reflecting a 9.13% increase compared to the end of the previous year[41] - The total assets increased to ¥2,477,888,881.18, up from ¥2,270,529,857.01, reflecting a growth of about 9.1% year-over-year[62] - The total liabilities amounted to ¥371,495,024.16, an increase from ¥325,073,996.38 in the previous year[30] - The non-current assets totaled ¥1,051,567,805.62, an increase from ¥939,433,440.52, reflecting a growth of approximately 11.9%[62] - The equity attributable to shareholders of the listed company was ¥2,106,393,857.02, up 8.27% from the previous year[41] Market and Strategic Initiatives - The company's operating revenue increased by 42.33% year-on-year, primarily due to a significant rise in sales volume of cosmetic active ingredient products[38] - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the report[64] - The company has been approved to issue convertible bonds to unspecified investors, which may enhance its capital structure[11] - The company plans to issue convertible bonds to unspecified objects, which has been approved by the Shenzhen Stock Exchange's listing review committee[27] Production and Profitability - The company's gross profit margin improved by 22.78 percentage points year-on-year, supported by enhanced production capacity utilization and the gradual release of new product capacity[44] - The weighted average return on net assets was 7.91%, an increase from 3.58% in the previous year[41] Audit and Reporting - The report was not audited, which may impact the perception of the financial results presented[55]